Future studies using human NSCLC specimens are warranted to compare various factors, such as the amount, density, and type of tumor-infiltrating immune cells, clinical factors (including smoking history), genetic mutations of cancer cells, estrogen levels, and ER expression, to elucidate the influence of estrogen on tumor immunity in NSCLC. This evidence concerns the gene ESR1 and neoplasm.